Figure 3.

Niraparib reduces the expression of MCL-1 and BCL-XL, enhances BIM levels, and promotes autophagic flux. a. Spiky ovarian cancer cells and SUM149 and BT474 mammary tumor cells were treated with vehicle control or niraparib (2 μM), for 4h and 8h. Cells were fixed in place and at least forty cells per condition were imaged in independent triplicate and the intensity ratio of phosphorylated protein levels to total protein expression plotted as a percentage of control treatment (n = 3 +/- SD). # p < 0.05 greater than vehicle control; * p < 0.05 less than vehicle control. b. Tumor cells were transfected with a plasmid to express LC3-GFP-RFP. Twenty-four h after transfection cells were treated with vehicle control or with niraparib (2 μM) for 4h and 8h. At each time point the mean number of intense GFP+ and RFP+ punctae were determined in at least 40 cells in independent triplicate (n = 3 +/- SD).